Dixon Tech, ICICI Securities and more: Top Stock on Broker’s radar for 22 May

BNP Paribas India has retained its outperform rating on Dixon Technologies at a target price at 17,910. Analysts stated that the company gave a notable FY25 with double revenue with double revenue, maintaining a balance-sheet strength, high-fixed-asset turnover, high returns on equity and strong operating cash-flow generation.While Dixon continues to capture a large part of the domestic mobile-phone total addressable market and large export opportunities, it is evaluating partnership for non-semiconductor components, apart from performance, they expect such forces to ensure the client’s viscosity and promote the margins profile of the company, promote the effects of the company by the company.Elara Securities India has made an accumulated rating on India Electronics with a price of Rs 400. Analysts stated that the company surprised positive in FY 25, which reached the highest margin in its history. Its products also demonstrated proven abilities during the recent India-Pakistan conflict, resulting in export inquiries. Analysts raised the target price due to the war-ride product portfolio, strong order visibility, which proceeded from export opportunities, as well as the possibility of surprise on the reverse margin.Emkay Global Financial Services has reduced Hindalcoto from selling, and has increased the target price to Rs 650 before Rs 600. Analysts stated that large -scale prices with major concerns and structurally positive attitude on LME aluminum, a selling rating was no longer warrant. The company posted a strong Q4 with business Ebitda worth Rs 9,770 crore, above estimates. It was powered by a strong aluminum upstream performance on low input costs and better feeling.Supported by Hindalco’s strong mass marrow number and better cost Outlook, captive coal and lower alumina costs, strengthened its upstream Ebitda-Per-Tonne growth capacity.An ad rating on ICICI securities with a target price at ICICI Securities Rs 5,450. Analysts stated that the fizzle’s public-outperform was powered by a strong green in the Ebitda margin. He said that its revenue growth for the quarter was probably operated by major brands such as Privainar -13, Bicosulus, MiniPress -AXL and mucane. In FEB’25, PFIZER had given a like-license to CNS brand Ativan and Pacitane for five years for Mylan, which would also help PFizer to trim their overhead costs during the trimester.In addition, Zoetis Pharma is expected to further improve its cash balance with the sale of its Thane land.Motilal Oswal Financial Services has a neutral rating on Semenswith, the target price of Rs 3,200. In its analyst meeting, the company focused its continuous focus on improvement in margin as volumes improved in segments. Analysts said the company’s smart infrastructure is benefiting from better demand and the digital industry segment is going down in terms of weakness of demand. Its mobility segment volume will improve as locomotive delivery begins after some quarters.The company intends to increase export stake in both smart infrastructure and dynamics.Disclaimer: The opinion, analysis and recommendations expressed here are of brokerage and do not reflect the views of the Times of India. Always consult a qualified investment advisor or financial planner before taking any investment decision.